PD-1 blockage delays murine squamous cell carcinoma development

Carcinogenesis

Volumn 35, Issue 2, 2014, Pages 424-431

  Belai, Eduardo Bertoli ^a   de Oliveira, Carine Ervolino ^a   Gasparoto, Thaís Helena ^a   Ramos, Rodrigo Nalio ^a   Torres, Sergio Aparecido ^a   Garlet, Gustavo Pompermaier ^a   Cavassani, Karen Angélica ^b   Silva, João Santana ^a   Campanelli, Ana Paula ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKERATIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; PROGRAMMED DEATH 1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LYMPHOCYTE ACTIVATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FLOW CYTOMETRY; IMMUNOENZYME TECHNIQUES; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; PAPILLOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; TETRADECANOYLPHORBOL ACETATE;

EID: 84893417533     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt305     Document Type: Article

References (62)

1. Coussens,L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860-867.
2. Ladoire,S. et al. (2011) Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol. Immunother., 60, 909-918.
3. Joffre,O. et al. (2009) Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev., 227, 234-247.
4. Iwai,Y. et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA, 99, 12293-12297.
5. Dong,H. et al. (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med., 5, 1365-1369.
6. Keir,M.E. et al. (2007) PD-1 and its ligands in T-cell immunity. Curr. Opin. Immunol., 19, 309-314.
7. Blank,C. et al. (2007) Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother., 56, 739-745.
8. Freeman,G.J. (2008) Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc. Natl Acad. Sci. USA, 105, 10275-10276.
9. Okazaki,T. et al. (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol., 19, 813-824.
10. Barber,D.L. et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439, 682-687.
11. Greenwald,R.J. et al. (2005) The B7 family revisited. Annu. Rev. Immunol., 23, 515-548.
12. Freeman,G.J. et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 192, 1027-1034.
13. Okazaki,T. et al. (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med., 9, 1477-1483.
14. Nishimura,H. et al. (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 11, 141-151.
15. Nishimura,H. et al. (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 291, 319-322.
16. Bu,D.X. et al. (2011) Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler. Thromb. Vasc. Biol., 31, 1100-1107.
17. Furukawa,Y. et al. (2000) Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2. Am. J. Pathol., 157, 473-484.
18. Carter,L.L. et al. (2007) PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol., 182, 124-134.
19. Singh,A.K. et al. (2011) Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy, 66, 155-162.
20. Sakuishi,K. et al. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med., 207, 2187-2194.
21. Blank,C. et al. (2006) Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer, 119, 317-327.
22. Ahmadzadeh,M. et al. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114, 1537-1544.
23. Gehring,A.J. et al. (2009) Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology, 137, 682-690.
24. Nomi,T. et al. (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res., 13, 2151-2157.
25. Thompson,R.H. et al. (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res., 13, 1757-1761.
26. Cho,Y.A. et al. (2011) Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol., 47, 1148-1153.
27. Malaspina,T.S. et al. (2011) Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol. Immunother., 60, 965-974.
28. Hald,J. et al. (1994) In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumourinfiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells. Cancer Immunol. Immunother., 39, 383-390.
29. Hald,J. et al. (1995) Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol. Immunother., 41, 243-250.
30. Bradburn,J.E. et al. (2007) The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells. Anticancer Res., 27(6B), 3819-3827.
31. Markey,A.C. et al. (1991) Expression of simple epithelial keratins 8 and 18 in epidermal neoplasia. J. Invest. Dermatol., 97, 763-770.
32. Leigh,I.M. et al. (1993) Keratinocyte alterations in skin tumour development. Recent Results Cancer Res., 128, 179-191.
33. Ichikawa,E. et al. (2004) Expression of keratin and involucrin in keratoacanthoma: an immunohistochemical aid to diagnosis. J. Dermatol. Sci., 34, 115-117.
34. Lavrijsen,A.P. et al. (1989) Expression of EGF receptor, involucrin, and cytokeratins in basal cell carcinomas and squamous cell carcinomas of the skin. Arch. Dermatol. Res., 281, 83-88.
35. Moll,R. et al. (1984) Differences of expression of cytokeratin polypeptides in various epithelial skin tumors. Arch. Dermatol. Res., 276, 349-363.
36. Yu,H. et al. (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol., 7, 41-51.
37. Ramos,R.N. et al. (2012) CD25+ T cell depletion impairs murine squamous cell carcinoma development via modulation of antitumor immune responses. Carcinogenesis, 33, 902-909.
38. Gasparoto,T.H. et al. (2010) Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment. Cancer Immunol. Immunother., 59, 819-828.
39. Solinas,G. et al. (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol., 86, 1065-1073.
40. Lavialle,C. et al. (1989) The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review). Anticancer Res., 9, 1265-1279.
41. Tsubokawa,F. et al. (2002) Heterogeneity of expression of cytokeratin subtypes in squamous cell carcinoma of the lung: with special reference to CK14 overexpression in cancer of high-proliferative and lymphogenous metastatic potential. Pathol. Int., 52, 286-293.
42. He,Q.Y. et al. (2004) Diverse proteomic alterations in gastric adenocarcinoma. Proteomics, 4, 3276-3287.
43. Lau,A.T. et al. (2007) The possible role of cytokeratin 8 in cadmiuminduced adaptation and carcinogenesis. Cancer Res., 67, 2107-2113.
44. Tischkowitz,M. et al. (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 7, 134.
45. Kabos,P. et al. (2011) Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res. Treat., 128, 45-55.
46. Krempski,J. et al. (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J. Immunol., 186, 6905-6913.
47. Schioppa,T. et al. (2011) B regulatory cells and the tumor-promoting actions of TNF-a during squamous carcinogenesis. Proc. Natl Acad. Sci. USA, 108, 10662-10667.
48. Shah,S. et al. (2005) Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer, 117, 574-586.
49. Biswas,S.K. et al. (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol., 11, 889-896.
50. Mantovani,A. et al. (2009) Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol., 70, 325-330.
51. Siveen,K.S. et al. (2009) Role of macrophages in tumour progression. Immunol. Lett., 123, 97-102.
52. Chiodi,F. (2010) New therapy to revert dysfunctional antibody responses during HIV-1 infection. J. Clin. Invest., 120, 3810-3813.
53. Caruso,R.A. et al. (2012) Neutrophil-tumor cell phagocytosis (cannibalism) in human tumors: an update and literature review. Exp. Oncol., 34, 306-311.
54. Yao,S. et al. (2009) PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood, 113, 5811-5818.
55. Abel,E.L. et al. (2009) Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat. Protoc., 4, 1350-1362.
56. Ridd,K. et al. (2006) Association of gene expression with sequential proliferation, differentiation and tumor formation in murine skin. Carcinogenesis, 27, 1556-1566.
57. Niu,Y. et al. (2002) Expression of CD44V6 and PCNA in squamous cell carcinomas. Chin. Med. J. (Engl)., 115, 1564-1568.
58. Dunn,G.P. et al. (2005) A critical function for type I interferons in cancer immunoediting. Nat. Immunol., 6, 722-729.
59. Ikushima,H. et al. (2010) TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer, 10, 415-424.
60. Bierie,B. et al. (2006) TGF-beta and cancer. Cytokine Growth Factor Rev., 17, 29-40.
61. Levy,L. et al. (2006) Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev., 17, 41-58.
62. Bierie,B. et al. (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer, 6, 506-520.